VRTX - VERTEX PHARMACEUTICALS INC / MA
IEX Last Trade
407.63
-66.530 -16.321%
Share volume: 0
Last Updated: Tue 24 Dec 2024 06:01:13 PM CET
Research and Development in Biotechnology (except Nanobiotechnology):
35.29%
PREVIOUS CLOSE
CHG
CHG%
$474.16
-66.53
-14.03%
Fundamental analysis
46%
Profitability
67%
Dept financing
7%
Liquidity
62%
Performance
30%
Performance
5 Days
2.75%
1 Month
-11.59%
3 Months
-11.60%
6 Months
-13.85%
1 Year
0.72%
2 Year
42.06%
Key data
Stock price
$407.63
DAY RANGE
$402.56 - $474.16
52 WEEK RANGE
$396.14 - $519.88
52 WEEK CHANGE
$0.03
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/04/2024
Company detail
CEO: Reshma Kewalramani
Region: US
Website: vrtx.com
Employees: 4,800
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: vrtx.com
Employees: 4,800
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Vertex Pharmaceuticals Incorporated engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with CF 6 years of age or older who have at least one F508del mutation. Its pipeline includes VX-864 for the treatment of AAT deficiency, which is in Phase 2 clinical trial.
Recent news